(Reuters) -The U.S. Food and Drug Administration has approved AbbVie’s drug to treat adults with a type of lung cancer who have received previous treatment, the drugmaker said on Wednesday.
The treatment, branded as Emrelis, belongs to a class of drugs known as antibody-drug conjugates (ADC) which are targeted cancer therapies.
Emrelis was approved for previously treated patients with non-squamous non-small cell lung cancer whose disease has spread to areas near the lungs or to other parts of the body, and who also have a high c-Met protein overexpression.
The c-Met protein is associated with poor prognosis, the company said.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)
